Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:CVRSNASDAQ:IRTCNASDAQ:PRCTNASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRSCorindus Vascular Robotics$4.27$4.27$0.78▼$4.40$891.09MN/A1.99 million shsN/AIRTCiRhythm Technologies$153.96-0.5%$137.50$55.92▼$157.13$4.94B1.4480,204 shs337,597 shsPRCTPROCEPT BioRobotics$57.60+1.2%$57.58$47.04▼$103.81$3.15B1.1836,542 shs554,155 shsSLNOSoleno Therapeutics$83.78+0.6%$76.89$39.41▼$86.79$4.20B-2.69786,105 shs1.34 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRSCorindus Vascular Robotics0.00%0.00%0.00%0.00%0.00%IRTCiRhythm Technologies-0.48%+1.99%+8.91%+44.05%+43.03%PRCTPROCEPT BioRobotics+1.21%-1.94%-1.71%+0.89%-5.71%SLNOSoleno Therapeutics+0.64%+2.90%+14.39%+22.74%+105.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRSCorindus Vascular RoboticsN/AN/AN/AN/AN/AN/AN/AN/AIRTCiRhythm Technologies1.0429 of 5 stars2.51.00.00.02.10.80.6PRCTPROCEPT BioRobotics2.5162 of 5 stars3.41.00.00.02.23.30.6SLNOSoleno Therapeutics4.663 of 5 stars4.52.00.04.62.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRSCorindus Vascular Robotics 0.00N/AN/AN/AIRTCiRhythm Technologies 2.90Moderate Buy$138.60-9.98% DownsidePRCTPROCEPT BioRobotics 2.86Moderate Buy$90.0056.25% UpsideSLNOSoleno Therapeutics 3.09Buy$107.1027.83% UpsideCurrent Analyst Ratings BreakdownLatest CVRS, SLNO, IRTC, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025SLNOSoleno TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy6/23/2025SLNOSoleno TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$110.006/11/2025IRTCiRhythm TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $160.005/22/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $167.005/8/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$81.00 ➝ $97.005/8/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.005/2/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$152.00 ➝ $139.005/2/2025IRTCiRhythm TechnologiesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$133.00 ➝ $150.005/2/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$104.00 ➝ $130.005/2/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $151.004/25/2025PRCTPROCEPT BioRoboticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$104.00 ➝ $84.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRSCorindus Vascular RoboticsN/AN/AN/AN/AN/AN/AIRTCiRhythm Technologies$591.84M8.30N/AN/A$2.90 per share53.09PRCTPROCEPT BioRobotics$224.50M14.20N/AN/A$7.71 per share7.47SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRSCorindus Vascular RoboticsN/AN/A0.00∞N/AN/AN/AN/AN/AIRTCiRhythm Technologies-$113.29M-$3.14N/AN/AN/A-15.90%-101.04%-9.55%7/30/2025 (Estimated)PRCTPROCEPT BioRobotics-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%7/30/2025 (Estimated)SLNOSoleno Therapeutics-$175.85M-$4.62N/AN/AN/AN/A-77.52%-63.44%8/6/2025 (Estimated)Latest CVRS, SLNO, IRTC, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025SLNOSoleno Therapeutics-$1.14-$0.95+$0.19-$0.95N/AN/A5/1/2025Q1 2025IRTCiRhythm Technologies-$0.89-$0.95-$0.06-$0.97$153.39 million$158.68 million4/24/2025Q1 2025PRCTPROCEPT BioRobotics-$0.49-$0.45+$0.04-$0.45$65.39 million$69.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRSCorindus Vascular RoboticsN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRSCorindus Vascular RoboticsN/AN/AN/AIRTCiRhythm Technologies7.475.715.58PRCTPROCEPT BioRobotics0.138.957.75SLNOSoleno Therapeutics0.2119.6419.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRSCorindus Vascular RoboticsN/AIRTCiRhythm TechnologiesN/APRCTPROCEPT BioRobotics89.46%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipCVRSCorindus Vascular RoboticsN/AIRTCiRhythm Technologies0.68%PRCTPROCEPT BioRobotics17.40%SLNOSoleno Therapeutics6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRSCorindus Vascular Robotics90208.69 millionN/ANot OptionableIRTCiRhythm Technologies2,00031.92 million31.71 millionOptionablePRCTPROCEPT BioRobotics43055.33 million45.70 millionOptionableSLNOSoleno Therapeutics3050.39 million47.17 millionOptionableCVRS, SLNO, IRTC, and PRCT HeadlinesRecent News About These CompaniesSoleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 20251 hour ago | finance.yahoo.comSoleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year High - What's Next?June 30 at 3:36 PM | marketbeat.comLisanti Capital Growth LLC Purchases Shares of 25,365 Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 29 at 6:33 AM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $22,410.50 in StockJune 26, 2025 | marketbeat.comSLNO Soleno Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comSoleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceJune 25, 2025 | santelog.comSSoleno gains as Betaville cites buyout interest (update)June 24, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year High - Here's What HappenedJune 23, 2025 | marketbeat.comSoleno Therapeutics initiated with a Buy at TD CowenJune 23, 2025 | msn.comFDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%June 23, 2025 | msn.comSoleno Therapeutics (NASDAQ:SLNO) Coverage Initiated at TD CowenJune 23, 2025 | marketbeat.comSoleno Therapeutics: Overbought On VYKAT Approval EnthusiasmJune 22, 2025 | seekingalpha.comGAMMA Investing LLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)June 22, 2025 | marketbeat.comPiper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR ProspectsJune 20, 2025 | msn.comSoleno Therapeutics to Present Research Findings at 2025 International Prader-Willi Syndrome ConferenceJune 20, 2025 | quiverquant.comQSoleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceJune 20, 2025 | globenewswire.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.com434,514 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month High - Here's What HappenedJune 12, 2025 | marketbeat.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Harbor Capital Advisors Inc.June 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVRS, SLNO, IRTC, and PRCT Company DescriptionsCorindus Vascular Robotics NYSEAMERICAN:CVRS$4.27 0.00 (0.00%) As of 11/27/2019Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures. Its CorPath system allows the physician to perform procedures with a control console located within an interventional cockpit; and CorPath GRX system enables the precise robotic-assisted control of guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.iRhythm Technologies NASDAQ:IRTC$153.96 -0.75 (-0.48%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$153.92 -0.05 (-0.03%) As of 08:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.PROCEPT BioRobotics NASDAQ:PRCT$57.60 +0.69 (+1.21%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$57.87 +0.27 (+0.47%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Soleno Therapeutics NASDAQ:SLNO$83.78 +0.53 (+0.64%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$81.24 -2.54 (-3.03%) As of 08:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
